What is Pyxis Oncology Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Pyxis Oncology's Probability of Financial Distress (%) is 0.07%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of Pyxis Oncology's Probability of Financial Distress (%)
For the Biotechnology subindustry, Pyxis Oncology's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pyxis Oncology's Probability of Financial Distress (%) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pyxis Oncology's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where Pyxis Oncology's Probability of Financial Distress (%) falls into.
Pyxis Oncology Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | -7.27 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 0.07% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
Pyxis Oncology (Pyxis Oncology) Business Description
Traded in Other Exchanges
N/A
Address
150 Cambridgepark Drive, Cambridge, MA, USA, 02140
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its lead ADC product candidate is PYX-201, an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that initially develop for solid tumors, including NSCLC, hormone receptor-positive breast, ovarian and thyroid cancer. The IO product candidate is PYX-106, designed to block Siglec-15-mediated suppression of T-cell proliferation and function.
Executives
| Pamela Ann Connealy |
officer: Chief Financial Officer |
320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
| Jitendra Wadhane |
officer: Chief Accounting Officer |
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
| Lara Sullivan |
director, officer: Chief Executive Officer |
C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850 |
| Jakob Dupont |
director |
C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
| Pfizer Inc |
10 percent owner |
66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192 |
| Pfizer Ventures (us) Llc |
10 percent owner |
66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192 |
| Rachel Humphrey |
director |
C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121 |
| Plc Barclays |
10 percent owner |
1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP |
| Mark Chin |
other: Former Director |
20 BERKELEY SQUARE, MAYFAIR, LONDON X0 W1J 6EQ |
| Darren S Cline |
director |
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
| Thomas Civik |
director |
C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141 |
| Cormorant Asset Management, Lp |
10 percent owner |
200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
| Bayer World Investments B.v. |
10 percent owner |
ENERGIEWEG 1, MIJDRECHT P7 3641 |
| Freda C Lewis-hall |
director |
C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
| Ronald Herbst |
officer: Chief Scientific Officer |
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Pyxis Oncology (Pyxis Oncology) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PYXS has been successfully added to your